Blog - Recent changes to laboratory certificates from RASL

Scientists using liquid chromatography

Clients may have seen some changes in the reporting format of urine drug test certificates issued by Racing Analytical Services Ltd (RASL).  The general structure of the report remains unchanged, with;

  • an upper panel identifying the characteristics of the donor, testing location, test dates chain of custody compliance, etc;
  • a middle panel establishing the integrity criteria for urine specimens (including creatinine and urea concentrations, pH, specific gravity);
  • a lower panel describing the drug test criteria for screening and for confirmation including AS/NZS cut-off concentrations.

These panels are followed by a text section describing the outcomes of the screening and confirmation test processes, indicating whether the test result is confirmed positive or negative and providing the confirmation concentration of target drugs.

The changes are twofold:

  1. In the integrity panel, the test SAMPLE CHECK (with an acceptable range 80% - 105%) has been replaced with OXIDANT (acceptable range <50ug/mL). The oxidant test is a refined version of the sample check and is more sensitive to potential adulterants in urine specimens.
  2. In addition, all five integrity markers (creatinine, specific gravity, oxidant, pH and urea) now have a test method prefixed EM rather than CD. The CD prefix relates to the test method using CEDIA (cloned enzyme donor immunoassay) technology – a specific type of immunoassay. EM denotes EMIT (enzyme multiplied immunoassay technique) which has been adopted at RASL due to improved test performance.

EMIT has also replaced CEDIA in the drug test panel. With the new EMIT tests, the amphetamines and ecstasy are reported as two separate tests (instead of all-inclusive as the previous CEDIA).  With the ecstasy panel, it has a higher cross-reactivity for some drugs, such as pseudoephedrine, than the amphetamine panel, and so can more reliably detect non-negative pseudoephedrine. 

For confirmation analysis, the sensitive and specific liquid chromatography/mass spectrometry (LCMS) methods (denoted by MS prefixes in the drug test panel) remain unchanged.

Oral fluid screening and confirmation tests are unchanged, using LCMS.

These changes mean greater selectivity, sensitivity and accuracy in laboratory analyses provided by RASL.

Boilerplate John